Tinea Pedis Clinical Trial
Official title:
Phase 3, Multicenter, Double-blind, Randomized, Non-inferiority Clinical Trial of Dapaconazole Cream 2% (Biolab Sanus Farmacêutica Ltda.) Versus Ketoconazole Cream 2% (Nizoral®, Janssen-Cilag Farmacêutica Ltda.) in Patients With Tinea Pedis
Verified date | July 2020 |
Source | Biolab Sanus Farmaceutica |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The main purpose of this study is to demonstrate that dapaconazole cream 2% (experimental drug) is non-inferior to ketoconazole cream 2% (Nizoral® - active comparator) for the treatment of dermatological lesions of Tinea pedis, when applied to the skin (topically) once daily during 28 days. Additionally, the safety and tolerability aspects will be evaluated in a descriptive way, through the observation of the incidence of adverse events.
Status | Completed |
Enrollment | 360 |
Est. completion date | November 12, 2019 |
Est. primary completion date | August 27, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility |
Inclusion Criteria: - Participants aged from 18 to 65 years old, male, or female with no childbearing potential or who are using an effective contraceptive method and who do not plan to become pregnant during the study period. - Presence of dermatological lesion(s) of Tinea pedis, with a global clinical severity score = 4, being a minimum score of 2 for itching or desquamation/maceration and a minimum score of 2 for erythema, having, also, the diagnosis confirmed by direct mycological (KOH) test. - No previous treatment with antimycotic medication, in the last 2 months, for the current dermatologic lesion. - No evidence of other significant diseases, that, at the investigator's discretion, may affect the participation in the clinical trial, in accordance with the protocol requirements. - Ability to understand the nature and the objective of the clinical trial, including the risks and possible side effects; intention to cooperate with the investigator and act in accordance with the protocol requirements, as confirmed by the informed consent form signature. Exclusion Criteria: - Existing hepatic and/or renal diseases or other pathologic findings, which might interfere with the safety and tolerability of the active ingredients. - Screening laboratory tests presenting deviations deemed as clinically significant, which, due to possible risks, prevents the participation in clinical trial. - Known hypersensitivity to ketoconazole or to chemically related compounds (azoles) or to the compounds of the investigational products. - Participants with severe or multiple drugs allergies, unless judged by the investigator as not clinically relevant to the participation in the clinical trial. - Positive anti human immunodeficiency virus (anti-HIV) test, positive Hepatitis B Surface Antigen (HBs-Ag) test or positive anti hepatitis C virus (anti-HCV) test. - Treatment, within 3 months prior to the start of the clinical trial treatment, with any drug known to have a well-established toxic potential to major organs. - Pregnant or lactating women - Participation in any clinical trial, or intake of any investigational product, within the last twelve months prior to the inclusion in the clinical trial. - Presence of onychomycosis. - Presence of "Moccasin type" Tinea pedis. - Presence of infected Tinea pedis, or any other infection or pathology that may confuse the treatment evaluation. - History of drug addiction. - Diseases that may alter the immune system and, consequently, the host's response to the fungal presence (immunosuppressed participants), as well as the use of systemic immunosuppressive drugs, chemotherapy or radiotherapy, during the 3 months prior to the start of treatment. - Use of drugs that may interfere with the assessment of the results, as well as use of topical immunosuppressants, topical antibiotics or topical corticosteroids, within 2 months prior to the start of treatment. - Use of antipruriginous drugs, including antihistaminics, within 72 hours prior to the start of treatment. - History of alcohol dependence and/or regular intake of alcoholic food or beverages containing = 20 g of pure ethanol per day. - Any prior treatment for the present lesion which, at investigator discretion, may interfere with the objectives of the clinical trial. - Participants who might be non-compliant to the study treatment and/or to the requirements and procedures of the protocol. - Participants who are unable to understand written and verbal instructions, in particular those regarding the risks and inconveniences to which they will be exposed during the participation in the clinical trial. |
Country | Name | City | State |
---|---|---|---|
Brazil | Galeno Desenvolvimento de Pesquisas Clinicas Ltda. - ME | Campinas | SP |
Lead Sponsor | Collaborator |
---|---|
Biolab Sanus Farmaceutica |
Brazil,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Proportion of participants with therapeutic cure | Proportion of participants, in each treatment group, who achieved therapeutic cure, defined as both clinical cure and mycological cure, on the assessment performed after 28 days of treatment. Clinical cure is defined as a score = 2 for the sum of scores attributed to each sign or symptom (erythema, maceration/peeling, fissuring/cracking, itching and burning) as evaluated by a four-point categorical scale (0=absent, 1=mild, 2=moderate, 3=severe). Mycological cure is defined as negative result for the direct mycological examination (potassium hydroxide [KOH] test) and a negative fungal culture. |
28 days of treatment | |
Secondary | Proportion of participants with therapeutic cure | Proportion of participants, in each treatment group, who achieved therapeutic cure, on the assessment performed after 42 days of treatment. | 42 days of treatment | |
Secondary | Proportion of participants maintaining therapeutic cure | Proportion of participants, in each treatment group, maintaining the therapeutic cure in the evaluation performed approximately 14 days after the end of the 42 days treatment period. | 14 (±3) days after the end of treatment | |
Secondary | Proportion of participants maintaining therapeutic cure | Proportion of participants, in each treatment group, maintaining the therapeutic cure in the evaluation performed approximately 28 days after the end of the 42 days treatment period. | 28 (±5) days after the end of treatment | |
Secondary | Number of days until clinical cure | Number of days elapsed between the day of start of treatment and the day when the clinical cure is diagnosed, according to the daily assessment, in each treatment group. | up to 42 days | |
Secondary | Number of adverse events per participant | Number of adverse events, in each treatment group, including clinically relevant alterations of vital signs and laboratory tests. | up to 80 (±5) days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05493488 -
A Trial to Evaluate the Safety and Efficacy of DBI-001 Gel, DBI-002 Gel, and Aqueous Gel in Subjects With Tinea Pedis
|
Phase 2 | |
Completed |
NCT04883593 -
A Study Comparing the Efficacy of TA103 and the Placebo Control in the Treatment of Interdigital Tinea Pedis.
|
Early Phase 1 | |
Terminated |
NCT02842021 -
Efficacy and Safety of Product S2G6T-1in Patients With Symptomatic Inflammatory Interdigital Tinea Pedis
|
Phase 2 | |
Completed |
NCT01712360 -
Pharmacokinetic Study of Pediatric Subjects With Tinea Cruris and Tinea Pedis
|
Phase 4 | |
Completed |
NCT00781664 -
Cumulative Irritation Test
|
Phase 1 | |
Completed |
NCT03676686 -
Study With Nåva Foot Cream in Patients With Tinea Pedis Interdigitalis
|
N/A | |
Completed |
NCT01519752 -
A Therapeutic Equivalence Study of Two Oxiconazole Nitrate Topical Cream Treatments for Patients With Tinea Pedis
|
Phase 1 | |
Completed |
NCT01580891 -
Evaluate the Clinical Equivalence of Two Naftifine HCl 1% Creams in Patients With Interdigital Tinea Pedis
|
Phase 1 | |
Completed |
NCT01353976 -
Safety and Efficacy of Econazole Nitrate Foam 1% in Subjects With Tinea Pedis
|
Phase 3 | |
Completed |
NCT01349998 -
Safety of a Topical Antifungal Treatment for Tinea Cruris, Tinea Pedis and Tinea Corporis
|
Phase 3 | |
Completed |
NCT04265521 -
Study With BioCool Footcare in Subjects With Tinea Pedis Interdigitalis and Heel Cracks, Calluses and/or Dry Feet
|
N/A | |
Completed |
NCT02633813 -
BE Study of Naftifine HCL
|
Phase 3 | |
Recruiting |
NCT00856596 -
Once a Day Topical Treatment for Athlete's Foot Fungus Inbetween the Toes in Males and Females
|
Phase 3 | |
Completed |
NCT00869336 -
Multicenter Study of the Efficacy and Safety of Luliconazole Cream in Tinea Pedis (Athlete's Foot)
|
Phase 2 | |
Completed |
NCT00768599 -
A Study of Econazole Foam 1% in Athlete's Foot
|
Phase 2 | |
Recruiting |
NCT00233493 -
Spread of Dermatophytes Among Families
|
N/A | |
Completed |
NCT03897257 -
A Comparison Study of UHE-103 Cream in Subjects With Moccasin Type Tinea Pedis
|
Phase 2 | |
Completed |
NCT03129321 -
Therapeutic Equivalence and Safety of Two Econazole Nitrate Cream, 1% Products in Tinea Pedis
|
Phase 3 | |
Completed |
NCT02335255 -
Evaluate Safety and Efficacy of Naftifine Hydrochloride Gel 2% and Naftin® Gel 2% in Tinea Pedis
|
Phase 1 | |
Withdrawn |
NCT02606383 -
Non-inferiority Phase III Trial Comparing Dapaconazole Cream 2% With Ketoconazole Cream 2% in Patients With Tinea Pedis
|
Phase 3 |